Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Resistance
Ciprofloxacin failure against TB due to rapid emergence of resistance
October 23rd, 2005
Ciprofloxacin failure against tuberculosis is due to the rapid emergence of resistance. "Studies of early bactericidal activity provide a fast and economic way to evaluate the clinical efficacy of potential agents for the treatment of tuberculosis. "Based on good early bactericidal activity data, ciprofloxacin entered further studies and is now recommended as part of treatment for multidrug-resistant tuberculosis," scientists writing in the journal Antimicrobial Agents and Chemotherapy report. "We examined the relationship between ciprofloxacin bactericidal activity and the emergence of resistance in an in vitro...
Source: Medical Letter on the CDC & FDA (2005-10-23)
|
